In mice bearing TRAIL-sensitive COLO 205 cells, systemic administration of low-dose (3 mg/kg) IgBD-TRAIL eradicated all large (~300 mm3) tumor grafts (Figure 1D), which triggered our interest to investigate the potential of IgBD-TRAIL in combating CRC with greater MDR. The gene discussed is TNFSF10; the disease is neoplasm.